Table 1: Baseline characteristics.

PatientsSex category (m: male/f: female)Age (years)Blood group1Kidney disease2HbA1c (%)C-reactive protein (g/l)Time on dialysis (months)Cumulative weekly dialysis dose (hours)Anticoagulation3Residual diuresis4Serum creatinine (μmol/l)Blood urea nitrogen (BUN) (mmol/l)Anti-Hbs antibodies (mIU/ml)5Number of previous transplantationsPanel reactive antibodies (%)

1m32A (+)25.77.15514.25UFH1.24083612.32114
2f660 (+)05.113.1608UFH1.43141810.22200
3m37A (+)05.3194714UFH1.221112310.59200
4m360 (-)25.2214415LMWH1.110129612.41200
5m46A (+)158.514213LMWH1.590127514.98010
6m61A (+)05.813.62712UFH1.0217787.84200
7m550 (-)04.812.99714LMWH1.541119314.42000
8f22A (+)05.21.24512UFH1.860104911.57200
9f490 (-)04.938815UFH2.14187110.132018
10f57A (+)04.82.74813Ar1.49010619.662025
11m28A (-)04.68.94415UFH1.120146912.652147
12f60B (+)34.54.34515UFH1.8412232.290070
13f53B (+)05.221.811114UFH1.74196411.431178
14f380 (+)38.913312UFH1.2608499.240078
15f56B (+)25.60.96813UFH1.610106913.632185
Median495.27.155141.49104911.439

. 14 Caucasians except patient no. 15 (Vietnamese). Furthermore, all patients received treatment with iron and recombinant erythropoietin. 1Blood group: (-): Rhesus negative; (+): Rhesus positive. 20: analgetics, cisplatine, ischaemia, orellanus, nephrosclerosis, pyelonephritis, CKD5D (unknown reasons), shrinkle kidneys, adult dominant polycystic kidney disease. 1: Alport syndrome; 2: focal segmental glomerulosclerosis; 3: diabetes mellitus. 3UFH: unfractionated heparin; LMWH: low molecular weight heparin; Ar: argatroban. 40: ≤500 ml; 1: >500 ml. 50: <10; 1: 10-100; 2: >100.